for people ages 18 years and up (full criteria)
study started
estimated completion
Principal Investigator
by Zev A. Wainberg (ucla)



A phase Ib, open-label platform study of select drug combinations chosen in order to characterize safety and tolerability of each treatment arm tested and to identify recommended doses and regimens for future studies.

Official Title

A Phase Ib, Multicenter, Open-label Dose Escalation and Expansion Platform Study of Select Drug Combinations in Adult Patients With Advanced or Metastatic BRAF V600 Colorectal Cancer


This is a phase Ib, multi-center, open-label study with multiple treatment arms in adult patients with advanced or metastatic BRAF V600 (E, D, or K) in order to characterize safety and tolerability of each treatment arm tested and to identify recommended doses and regimens for future studies. The open platform design of this study is adaptive to allow removal of combination treatment arm(s) based on emerging data and facilitate introduction of new candidate combinations. The study is comprised of a dose escalation part and may be followed by a dose expansion part for any combination treatment arm.


BRAF V600 Colorectal Cancer, Phase Ib, BRAF-mutated, BRAF V600E, BRAF V600D, BRAF V600K, colorectal cancer, colon cancer, rectal cancer, metastatic, BLRM with EWOC, Colorectal Neoplasms, Trametinib, Dabrafenib, Spartalizumab, LTT462, LXH254, TNO155, Tislelizumab


You can join if…

Open to people ages 18 years and up

  • Patients must have a site of disease amenable to biopsy, and be a candidate for tumor biopsy according to the treating institution's guidelines. Patients must be willing to undergo a new tumor biopsy at baseline and during on study therapy. Exceptions may be considered after documented discussion with Novartis.
  • All patients must have a BRAF V600 mutation confirmed by local assessment.
  • Patients with unresectable advanced/metastatic BRAF V600 cancer of the colon or rectum with measurable disease as determined by RECIST v1.1
  • Patients must have documented disease progression following, or are intolerant to, 1 or 2 lines of chemotherapy for advanced/metastatic disease

You CAN'T join if...

  • Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy, or in-situ cervical cancer, or other tumors that will not affect life expectancy
  • Impairment of gastrointestinal function or gastrointestinal disease that may signficantly alter the absorption of study drugs
  • History of or current evidence/risk of retinal verin occlusion or serous retinopathy
  • History of or current interstitial lung disease or non-infectious pneumonitis
  • Patients with a known history of testing positive for HIV
  • Clinically significant cardiac disease at screening
  • Any medical condition that would, in the investigator's judgment, prevent the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures.
  • Pregnant or lactating women

Other protocol-defined inclusion/exclusion may apply.


  • UCLA Medical Center Santa Monica Location accepting new patients
    Los Angeles California 90095 United States
  • University of Texas MD Anderson Cancer Center accepting new patients
    Houston Texas 77030 United States

Lead Scientist at UC Cancer

  • Zev A. Wainberg (ucla)
    HS Clinical Professor, Medicine. Authored (or co-authored) 108 research publications


accepting new patients
Start Date
Completion Date
Novartis Pharmaceuticals
Phase 1 research study
Study Type
Expecting 350 study participants
Last Updated